Currently Druggable in Prostate Cancer

A Drug Target Competitive Analysis

Product Code BSK00064
Publication Date September 2008
Publisher Bioseeker
Product Type Report
Pages 306
ISBN Number not applicable
Change currency
PDF £1,620.00 €1,951 $2,562 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Currently Druggable in Prostate Cancer

A Drug Target Competitive Analysis

This report aims to analyze the current and future potential of prostate cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

This report is written for you to identify your competition and understand which targeting strategies are at work within prostate cancer drug development. It allows you to pin-point which competitors drugs' clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the prostate cancer field and identified 135 drug targets belonging to 193 drugs. This report, Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of prostate cancer drugs.

In the report, BioSeeker reports on 116 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 193 prostate cancer drugs. The highest degree of distinctiveness among the cancer drugs is achieved by sorting each of them according to drug target mix, compound type and R&D approach. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of prostate drugs. No less than 300+ target-target interactions were recognized among and between 110 of the 135 included prostate cancer drug targets.

Why You Should Own Your Own Copy of this Report:

  • 300+ pages, with more than 50 different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
  • A 193 prostate cancer drugs analysis, under development by 135 investigators
  • 135 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other prostate cancer drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
  • A unique drug target combination breakdown of prostate cancer drugs into R&D approaches
  • Unique drug-protein target interactome- and protein-protein interactome of drug targets analysis
  • Pathway profiling of prostate cancer drug targets
  • Compound strategies based on sub-cellular localization of drug targets
  • Expression levels of identified drug targets in prostate cancer tissue
  • Structure based drug design in prostate cancer
  • Pin-point which competitor drugs' clinical out-come may have bearing on your own drug development
  • Who are working on sequels to blockbuster drugs?
  • Locate white-spots in the competitive landscape, giving you little or no competition

In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

Contents

  • Executive Summary
  • 2 About Cancer Highlights
  • 3 Methodologies
  • 4 Table of Contents
    • 4.1 List of Figures
    • 4.2 List of Tables
  • 5 How to Use this Report
  • 6 Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug Targets
  • 7 The Cancer Genome Project and Prostate Cancer Targets
    • 7.1 Prostate Cancer Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
  • 8 Expression Levels of Identified Drug Targets in Prostate Cancer Tissue
  • 9 Pathway Analysis of Prostate Cancer Drugs
  • 10 Target-Target Interactions among Identified Prostate Cancer Targets
  • 11 Structure-based Drug Design in Prostate Cancer is Stimulated by Available Structure Data on Biological Targets
  • 12 Drug Target Profiles of Prostate Cancer Drugs
    • 12.1.1 Acid Phosphatase Activity Targets
    • 12.1.2 Carboxy-Lyase Activity Targets
    • 12.1.3 Carboxypeptidase Activity Targets
    • 12.1.4 Catalytic Activity Targets
    • 12.1.5 Cell Adhesion Molecule Activity Targets
    • 12.1.6 Chaperone Activity Targets
    • 12.1.7 Chemokine Activity Targets
    • 12.1.8 Complement Activity Targets
    • 12.1.9 Cysteine-Type Peptidase Activity Targets
    • 12.1.10 Cytokine Activity Targets
    • 12.1.11 DNA Repair Protein Targets
    • 12.1.12 DNA Topoisomerase Activity Targets
    • 12.1.13 DNA-Directed DNA Polymerase Activity Targets
    • 12.1.14 G-Protein Coupled Receptor Activity Targets
    • 12.1.15 Growth Factor Activity Targets
    • 12.1.16 Hydrolase Activity Targets
    • 12.1.17 Kinase Activity Targets
    • 12.1.18 Ligand-Dependent Nuclear Receptor Activity Targets
    • 12.1.19 Ligase Activity Targets
    • 12.1.20 Lipid Kinase Activity Targets
    • 12.1.21 Lipid Phosphatase Activity Targets
    • 12.1.22 Metallopeptidase Activity Targets
    • 12.1.23 Molecular Function Unknown Targets
    • 12.1.24 Motor Activity Targets
    • 12.1.25 Oxidoreductase Activity Targets
    • 12.1.26 Peptide Hormone Targets
    • 12.1.27 Protein Binding Targets
    • 12.1.28 Protein Serine/Threonine Kinase Activity Targets
    • 12.1.29 Protein-Tyrosine Kinase Activity Targets
    • 12.1.30 Receptor Activity Targets
    • 12.1.31 Receptor Binding Targets
    • 12.1.32 Receptor Signaling Complex Scaffold Activity Targets
    • 12.1.33 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets
    • 12.1.34 RNA Binding Targets
    • 12.1.35 RNA-Directed DNA Polymerase Activity Targets
    • 12.1.36 Serine-Type Peptidase Activity Targets
    • 12.1.37 Structural Constituent of Cytoskeleton Targets
    • 12.1.38 Structural Molecule Activity Targets
    • 12.1.39 Superoxide Dismutase Activity Targets
    • 12.1.40 T Cell Receptor Activity Targets
    • 12.1.41 Transcription Factor Activity Targets
    • 12.1.42 Transcription Regulator Activity Targets
    • 12.1.43 Translation Regulator Activity Targets
    • 12.1.44 Transmembrane Receptor Activity Targets
    • 12.1.45 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
    • 12.1.46 Transporter Activity Targets
  • 13 The Drug-Target Interactome
  • 14 The Progression and Maturity of Prostate Cancer Targets
    • 14.1 Target Profiles of Prostate Cancer Drugs in Pre-Registration or on the Market
    • 14.2 New and Unique Prostate Cancer Targets in Phase III Clinical Development
    • 14.3 New and Unique Prostate Cancer Targets in Phase II Clinical Development
    • 14.4 New and Unique Prostate Cancer Targets in Phase I Clinical Development
    • 14.5 New and Unique Prostate Cancer Targets in Preclinical Development
    • 14.6 Development Profiles of All Prostate Cancer Target Combinations
  • 15 Targets by R&D Approach in Prostate Cancer
    • 15.1 Small Molecules
      • 15.1.1 Background
      • 15.1.2 Targets in Prostate Cancer
    • 15.2 Peptide/Protein Drugs
      • 15.2.1 Background
      • 15.2.2 Targets in Prostate Cancer
    • 15.3 Monoclonal Antibodies and Antibody-Like Structures
      • 15.3.1 Background
      • 15.3.2 Targets in Prostate Cancer
    • 15.4 Nucleic Acid Therapies
      • 15.4.1 Background
      • 15.4.2 Targets in Prostate Cancer
    • 15.5 Cell and Gene Therapy
      • 15.5.1 Background
      • 15.5.2 Targets in Prostate Cancer
    • 15.6 Drug Delivery and Nanotechnology
      • 15.6.1 Background
      • 15.6.2 Targets in Prostate Cancer
  • 16 Prostate Cancer Targets by Companies
    • 16.1 Australia
    • 16.2 Canada
    • 16.3 Denmark
    • 16.4 Finland
    • 16.5 France
    • 16.6 Germany
    • 16.7 India
    • 16.8 Ireland
    • 16.9 Israel
    • 16.10 Italy
    • 16.11 Japan
    • 16.12 Netherlands
    • 16.13 Norway
    • 16.14 Spain
    • 16.15 Sweden
    • 16.16 Switzerland
    • 16.17 United Kingdom
    • 16.18 USA
    • 16.19 Non-Industrial Bodies
  • 17 Drug Index
  • 18 Company Index
  • List of Figures
    • Figure 1: Distribution of Compound Types among Prostate Cancer Drugs
    • Figure 2: Primary Sub-cellular Localization of Drug Targets
    • Figure 3: Visualization of Protein-Protein Interactions Among Antibody Drug Targets
    • Figure 4: The Drug-Protein Interactome of Prostate Cancer Drugs Main Clusters
    • Figure 5: The Drug-Protein Interactome of Prostate Cancer Drugs Smaller Clusters
    • Figure 6: Head-to-Head Targeting Interactome of Prostate Cancer Drugs
  • List of Tables
    • Table 1: Compound Strategies based on Sub-Cellular Localization of Prostate Cancer Drug Targets
    • Table 2: Drug Targets of Prostate Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
    • Table 3: Expression Levels of Identified Drug Targets in Prostate Cancer Tissue
    • Table 4: Pathway Summary
    • Table 5: Drug Targets without any Identified Assigned Pathways
    • Table 6: Pathway Profile According to BioCarta of Prostate Cancer Drug Targets
    • Table 7: Pathway Profile According to BioCarta of Prostate Cancer Drug Targets
    • Table 8: Pathway Profile According to BioCarta of Prostate Cancer Drug Targets
    • Table 9: Target-Target Interactions among Prostate Cancer Drug Targets
    • Table 10: Identity of Prostate Cancer Drug Targets with Available Biological Structures
    • Table 11: Overview of Drug Target Profile Themes
    • Table 12: Drug-Protein Interactome Clusters
    • Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, and the Presence of New Drug Target Mixes by Developmental Stage
    • Table 14: Top 5 Competitive Prostate Cancer Targets
    • Table 15: Target Profiles of Prostate Cancer Drugs in Pre-Registration or on the Market
    • Table 16: New and Unique Prostate Cancer Targets in Phase III Clinical Development
    • Table 17: New and Unique Prostate Cancer Targets in Phase II Clinical Development
    • Table 18 New and Unique Prostate Cancer Targets in Phase I Clinical Development
    • Table 19: New and Unique Prostate Cancer Targets in Preclinical Development
    • Table 20: The Progression, Maturity and Competitive Comparison of Prostate Cancer Drug Targets in Development
    • Table 21: Number of Prostate Cancer Drug Target Mixes Reported by Line of Therapy
    • Table 22: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Prostate Cancer by Drug Target
    • Table 23: Drug Targets of Small Molecule Drugs in Prostate Cancer
    • Table 24: Mechanistic Relationship between Small Molecule Drugs in Prostate Cancer
    • Table 25: Drug Targets of Peptide Based Drugs in Prostate Cancer
    • Table 26: Drug Targets of Protein Based Drugs in Prostate Cancer
    • Table 27: Drug Targets of Monoclonal Antibodies and Antibody-Like Drugs in Prostate Cancer277
    • Table 28: Drug Targets of Nucleic Acid Therapies in Prostate Cancer
    • Table 29: Potential Forms of Cell Therapy
    • Table 30: Vectors in Gene Therapy
    • Table 31: Drug Targets of Cell Therapies in Prostate Cancer
    • Table 32: Drug Targets of Gene Therapies in Prostate Cancer
    • Table 33: Drug Targets with New Drug Delivery Strategies in Prostate Cancer
    • Table 34: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Australia
    • Table 35: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Canada
    • Table 36: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Denmark
    • Table 37: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Finland
    • Table 38: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in France
    • Table 39: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Germany
    • Table 40: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in India
    • Table 41: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Ireland
    • Table 42: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Israel
    • Table 43: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Italy
    • Table 44: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Japan
    • Table 45: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Netherlands
    • Table 46: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Norway
    • Table 47: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Spain
    • Table 48: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Sweden
    • Table 49: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in Switzerland
    • Table 50: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in United Kingdom
    • Table 51: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Companies in USA
    • Table 52: Prostate Cancer Drugs with Drug Target Mix and Developmental Projects by Non-Industrial Bodies